Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


Exhibit 10.6


 


LICENSING, MANUFACTURING

AND SUPPLY AGREEMENT


 


This Licensing, Manufacturing and Supply Agreement
(the “Agreement”) is being entered into as of the 5th day of December 2011 (the “Effective
Date”), by and between INNOCOLL PHARMACEUTICALS, LIMITED, an Irish Corporation (collectively, within its Affiliates “Innocoll”)
whose principal office is Midlands Innovation and Research Centre, Dublin Road, Athlone, Co. Westmeath, Ireland (or “Innocoll”)
and Saudi Centre for Pharmaceuticals, offices located at 341 Olaya Street, Riyadh, Saudi Arabia (“SCP”)


 


Preliminary Statements


 


WHEREAS, Innocoll has developed the Product
and desires to grant to SCP the exclusive right to distribute and sell the Product in the Territory in the Field (as each is defined
below);


 


WHEREAS, SCP is willing to act as Innocoll’s
distributor for the Product in the Territory in the Field; and


 


WHEREAS, Innocoll and SCP desire to enter into
this Agreement to set forth the terms and conditions of such distribution right and all other rights and obligations of the parties
relating thereto.


 


NOW, THEREFORE, the parties agree as follows:


 


Terms and Conditions


 


	1.		Defined Terms:



 


		1.1.	Affiliates shall mean, with respect to either party, those entities controlled by, in control
of, or under common control with such party. A corporation or non-corporate business entity shall be regarded as in control of
another corporation or business entity (i) if it owns or directly or indirectly controls a majority of the voting stock or other
ownership interest of the other entity, or (ii) in the absence of the ownership of a majority of the voting stock or other ownership
interest of such entity, if it possesses, directly or indirectly, the power to direct or cause the direction of the management
and policies of such corporation or non-corporate business entity, as applicable.



 


		1.2.	Field shall mean surgical adhesion barrier



 


		1.3.	Product shall mean product(s) identified in Exhibit A



 


		1.4.	Territory shall mean Saudi, UAE, Qatar, Oman, Kuwait, Bahrain, Jordan, Iraq



 


		1.5.	Net Sales shall mean the gross invoiced sales revenues received or receivable by SCP
                                                                                                                       from sales of Products, less the following items: (a) discounts allowed in amounts customary in the trade, contract
                                                                                                                       governmental and bid rebates; (b) sales, tariffs, duties and/or use taxes and other governmental charges; (c) charges
                                                                                                                       incurred in connection with exportation or importation to the extent separately stated on an invoice. In the case of any sale
                                                                                                                       of a Product for value other than in an arm’s length transaction exclusively for cash, such as barter or counter-trade,
                                                                                                                       Net Sales shall be determined by referencing Net Sales at which substantially similar quantities of such Product in the same
                                                                                                                       country in the Territory are sold in an arm’s length transaction for cash.



 




    	 



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

  


	2.		Appointment of Exclusive Distributor



 


		2.1.	Innocoll hereby appoints SCP as its sole and exclusive distributor to market, sell, advertise,
promote and distribute, directly or through its Affiliates the Product in the Field in the Territory. SCP hereby accepts such appointment.



 


		2.2.	Innocoll represents and warrants to SCP that Innocoll has not entered into any other agreements,
written or oral, with any third party permitting the sale or distribution of the Product in the Field in the Territory, and Innocoll
covenants and agrees that during the Term, Innocoll will not enter into any such agreement or itself, directly or indirectly, sell
or distribute the Product or any product that competes directly with the Product in the Territory.



 


	3.		Manufacture and Supply of Product



 


		3.1.	Forecasts. At the beginning of each calendar month during the Term, SCP shall provide Innocoll
with a non-binding, good faith written forecast of SCP’s expected requirements for Product during the following twelve (12)
month period (the “Forecast’). Notwithstanding the first sentence of this Section 3.1, the first three (3) month
period included in each Forecast shall constitute a firm purchase order and binding commitment.



 


		3.2.	Orders. SCP shall place binding orders for Product by written or electronic purchase order
(or by any other means agreed to by the parties) to Innocoll. Innocoll shall acknowledge and accept or reject any SCP purchase
order in writing within ten (10) days of receipt. All such purchase orders shall be irrevocable. Purchase orders shall set forth
the desired date of delivery with respect to the Product ordered and shall be placed at least ninety (90) days prior to such desired
date of delivery. All Product ordered by SCP under this Agreement shall be delivered on or before the delivery date set forth in
the applicable purchase order. The first purchase order for the initial quantities (“Initial Purchase”) will be placed
subject to the conditions outlined in Exhibit B.



 


		3.3.	Innocoll will manufacture the Products exclusively for SCP in accordance with the Specifications
and in compliance with all relevant legal and regulatory requirements.



 


		3.4.	Shipment. Innocoll shall deliver the Product, FCA (incoterms 2000) Saal, Germany or other
location as Innocoll may identify rom time to time in its discretion (the “Shipping Point”), and title and all
risk of loss shall pass to SCP upon delivery to the designated carrier at the Shipping Point. The parties will cooperate to obtain
the best commercial rates for shipping costs. SCP shall arrange for shipping in compliance with the applicable Product requirements
regarding temperature, duration and other environmental factors as required to properly preserve the Product without materially
impacting its shelf life. All Product delivered by Innocoll shall be suitably packed and marked for shipment to such SCP location
as SCP may designate. Innocoll shall ship all Product in accordance with the instructions specified in SCP’s purchase orders.
A Certificate of Analysis (“COA”) specific to testing of each lot/batch, must accompany each shipment. Innocoll
shall maintain a copy of each such COA in compliance with cGMP/QSR. Innocoll shall provide a duplicate copy of the COA to SCP,
upon SCP’s request.



 


		3.5.	Inspection and Acceptance. SCP shall have the right, at its sole discretion, to inspect
each and every shipment of the Product. SCP shall have fifteen (15) days from receipt of each shipment of Product to visually inspect
the shipment (“Inspection Period”). SCP may reject a shipment (or portion thereof) of Product if any
one or more units contained therein fail to conform to the Specifications, by providing Innocoll written notice of such rejection
prior to the end of the Inspection Period. SCP may then return all or a portion of the shipment of Product to Innocoll. In addition
to the foregoing, for any Product for which the defect identified by SCP is a latent defect that could not reasonably be



 




    	- 2 -



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 


detected upon visual
inspection, SCP shall have a period of thirty (30) days from the date of identification of such latent defect to return any such
Product to Innocoll.


 


	4.		Supply Prices and Additional Consideration



 


Product Supply Prices and Additional Consideration
are set out in Exhibit B which is incorporated herein by reference.


 


	5.		Payment Terms



 


		5.1.	For the first 5,000 boxes (25,000 units) shipped, the payment terms will be Letter of Credit upon
receipt of shipment.



 


		5.2.	For all subsequent shipments, payment will be due within 45 days of receipt of shipment.



 


	6.		Minimum Purchase Requirements



 


From the second calendar year subsequent to
approval in the Territory for the term of the Agreement, SCP will purchase Products from Innocoll in an amount as set out on Exhibit
C hereto (“Minimum Purchase Requirement”).


 


	7.		Complaints



 


SCP will inform Innocoll immediately of any
complaints related to the Products and will liaise with Innocoll in investigating the possible causes and agree on any remedial
plans of action.


 


	8.		Batch Recall



 


SCP shall be responsible for any batch recall
of Products from the market and co-ordinate the same. In the event any governmental authority or agency requests a recall or takes
similar action in connection with the Products, or in the event that SCP determines an event or incident has occurred which may
result in the need for a recall or a market withdrawal, SCP will inform Innocoll by telephone or facsimile within 24 hours and
the parties shall agree on an appropriate course of action. Innocoll shall bear the expense of any recall resulting from breach
of its obligations hereunder or from negligent manufacture, packaging or shipment of the Products by it. In a I other cases, SCP
shall bear the expense of any recall.


 


	9.		Auditing



 


		9.1.	During normal business hours, Innocoll shall provide access to its premises to SCP to permit audits
of the relevant documents and facilities by SCP. SCP shall be entitled to one (1) audit within each twelve (12) month period during
the Term.



 


		9.2.	Innocoll will ensure that any material deficiencies highlighted during any audit by SCP or Regulatory
Bodies will be dealt with as soon as is practically possible following receipt of an official signed Audit Report from SCP.



 


	10.		SCP Obligations



 


		10.1.	SCP shall be responsible for compiling, submitting and maintaining the Product registrations, and
all associated costs. Innocoll shall provide all relevant and available information and documentation to support the Product registrations
in English to SCP and SCP shall be responsible for all required translations. SCP will submit the Product registrations to the
Regulatory Authorities within one (1) month of receiving all required



 




    	- 3 -



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

  


information from
Innocoll. If SCP fails to submit the Product registration within one (1) month, the specific Product rights will revert
to Innocoll.


 


		10.2.	SCP shall launch the Product(s) within three (3) months of receiving Regulatory Approval. If SCP
fails to launch the product within three (3) months, the Product rights will revert to Innocoll.



 


		10.3.	SCP shall sell and distribute the Product in the Territory under the original trade-marks and packages
of Innocoll or under any modified trademarks or packages agreed by the Parties.



 


		10.4.	SCP shall provide at its own expense all staff and facilities necessary for the operation of the
distributorship and the fulfilment of the terms of this Agreement.



 


		10.5.	SCP shall handle and store the Products securely and with all due skill care and attention and
shall not take any step to alter the condition of any of the Products from that in which the Products are delivered by Innocoll.



 


		10.6.	At the request of Innocoll, SCP shall receive employees and representatives of Innocoll and shall
render to them all reasonable facilities for investigating conditions of trade and to visit customers in the Territory. Each party
shall bear their own costs relating to such visits.



 


		10.7.	SCP shall in good faith prepare and submit to Innocoll on or before January 15th in
each year a detailed marketing plan and budget (“the Plan”) for the promotion of the Products for the immediately succeeding
calendar year



 


		10.7.1.	In the event that the Plan is agreed upon by Innocoll and SCP, SCP shall use all reasonable endeavours
to ensure that it conforms to the Plan during the relevant calendar year.



 


		10.7.2.	SCP shall keep Innocoll informed of competition experienced in the Territory and when so requested
by Innocoll provide information on marketing activities and competitive products in the Territory.



 


		10.7.3.	SCP shall prepare all advertising promotional and marketing material for the Products and submit
the same to Innocoll for approval. On receipt of such approval (which shall not be unreasonably withheld or delayed) SCP shall
produce all such approved material at SCP’s expense.



 


		10.8.	SCP shall purchase the agreed annual minimum quantities defined in Exhibit C.



 


		10.9.	SCP has or will have and will maintain in force a product liability insurance which is covering
any and all liabilities of SCP relating to the Products.



 


	11.		Innocoll Obligations



 


		11.1.	Innocoll shall comply in all material respects with all laws, rules and regulations applicable
to the design, manufacture, labelling, packaging, storage and handling of the Product in the Territory, including maintaining qualified
manufacturing and quality facilities and/or procedures. Innocoll shall ensure that all third-party manufacturers of any raw materials
for the Product comply in all material respects with all laws, rules and regulations applicable to the design, manufacture, labelling
and packaging of the Product in the Territory. Without limiting the generality of the foregoing, Innocoll (and all third-party
manufacturers of any raw materials for Product) shall implement such quality



 




    	- 4 -



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

  


control systems and
procedures as shall be appropriate to ensure compliance with the requirements of ISO and cGMP/QSR, which are applicable to Innocoll
or such third-party manufacturer as the manufacturer and supplier of the Product. Innocoll shall allow reasonable access to its
records, manufacturing facilities, and its third-party manufacturers’ manufacturing facilities and records (if applicable)
to allow any Regulatory Authority to conduct full compliance audits or inspections relating to the Product. Innocoll and any third
party manufacturer shall ensure that the Products are manufactured in strict compliance with the Specifications.


 


		11.2.	Innocoll hereby undertakes to sell the Products to SCP at the prices determined in accordance with
Exhibit B hereof and on terms and conditions in accordance with the provisions hereof.



 


		11.3.	Innocoll will without delay approve as appropriate the material for the advertising promotion and
marketing of the Products in the Territory as submitted by SCP.



 


		11.4.	Upon giving six months’ notice in writing Innocoll shall be entitled at its discretion to:



 


		11.4.1.	discontinue the manufacture of the Products;



 


		11.4.2.	or make changes or introduce modifications new presentations enhancements or improvements to the Products the Products’ packaging or branding or any part thereof; or



 


		11.4.3.	introduce new additional or replacement products.



 


		11.5.	Innocoll has and will maintain in force a product liability insurance which is covering any and
all liabilities of Innocoll relating to the Products.



 


	12.		Confidentiality Obligations



 


		12.1.	Each party agrees to maintain during the term of this Agreement and for a period of ten (10) years
thereafter the strictest confidence with regard to the confidential and/or proprietary information, in whatever medium, relating
to the Products and their manufacture, and any other information disclosed to it under this Agreement by the other party and proprietary
to it or its affiliates or any third party contract partners (the “Confidential Information”). Neither party
shall directly nor indirectly pass on the Confidential Information to others nor use it for any purpose not mentioned in this Agreement.
Each party shall have the right to disclose the other party’s Confidential Information to its employees or advisors who need
this knowledge for the purposes authorized herein. To the extent that a party discloses Confidential Information to an employee
or advisor, such party will be responsible for any failure by such persons or entities to hold such information in confidence or
use such information solely for the purposes of this Agreement.



 


		12.2.	The obligations of confidentiality and use restrictions set forth herein above will not apply to
the following information:



 


		12.2.1.	information that is or becomes publicly known or available by publication, commercial use or otherwise
without breach of this Agreement by the receiving party;



 


		12.2.2.	information that the receiving party rightfully receives from a third party without a restriction
on disclosure;



 




    	- 5 -



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

  


		12.2.3.	information that must be disclosed pursuant to governmental and regulatory requirements (including
Certification Audits);



 


		12.2.4.	information that is independently developed by employees of the receiving party who nave not had
access to the Confidential Information; or



 


		12.2.5.	information that is known by the receiving party at the time of receipt.



 


	13.		Proprietary Rights



 


		13.1.	All Know-how (all manufacturing and technical data, instructions, specifications and experiences
regarding the Products as well as test methods developed) documented in the Specifications is owned by Innocoll (“Innocoll
Know-How”). Innocoll shall have a limited, royalty-free license to use the Innocoll Know-How in accordance with and for
the term of this Agreement.



 


		13.2.	Innocoll represents and warrants that Innocoll’s manufacturing methods do not infringe any
third party’s proprietary rights. Innocoll will indemnify and hold harmless SCP for any and all claims arising out of or
based on claims related to the intellectual property rights underlying such methods.



 


	14.		Warranties and Liability



 


		14.1.	Innocoll shall be responsible for all claims related to the Product to the extent arising from
(a) the gross negligence or wilful misconduct of Innocoll in the manufacturing of the Products, (b) a material breach of this Agreement
by Innocoll or (c) material breach of any law or regulation (that Innocoll is required to comply with hereunder) by Innocoll. SCP
shall be responsible for all claims related to the Product to the extent arising from:  (a) the gross negligence or wilful
misconduct of SCP in the marketing and promotion of products, (b) material breach of this Agreement by SCP or (c) material breach
of any law or regulation (that SCP is required to comply with hereunder) by SCP.



 


	15.		Indemnities



 


		15.1.	As soon as a party becomes aware of the possibility of a claim involving indemnification under
this article, the indemnified party shall give the indemnifying party prompt notice in writing and shall permit the indemnifying
party to have control over and conduct the defense of such claim or suit. The indemnified party agrees to provide all reasonable
information and assistance to the indemnifying party in such defense.



 


		15.2.	Innocoll shall indemnify and hold SCP harmless against all claims and expenses, including reasonable
legal expenses, arising out of the death or injury to any person or persons or out of any damages to property, whether during or
following the termination or expiration of this Agreement, resulting from the use of any products into which the Products were
incorporated where such death, injury or damage is attributable to any defect in a Product attributable to any negligent, reckless
or intentional act or omission by Innocoll, or the breach of this Agreement by Innocoll.



 


		15.3.	SCP shall indemnify and hold Innocoll harmless against all claims and expenses, including reasonable
legal expenses, arising out of the death or injury to any person or persons or out of any damages to property, whether during or
following the expiration or termination of this Agreement, resulting from the use of any products into which the Products were
incorporated where such death, injury or damage is attributable to any negligent, reckless or intentional act or omission by SCP,
or the breach of this Agreement by SCP.



 




    	- 6 -



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

  


	16.		Term and Termination



 


		16.1.	This Agreement shall become effective on the Effective Date and shall continue for five (5)
years.



 


		16.2.	Each party shall be entitled to terminate the Agreement with immediate effect for material cause.
“Material cause” shall include, but not be limited to, the following:



 


		16.2.1.	if SCP fails to pay for the Products within the time set forth in Clause 5.1 & 5.2 above, if
SCP should fail to meet the minimum purchase obligations as specified in Exhibit C, or if SCP is otherwise in breach of its obligations
under this Agreement; then Innocoll, may, at its option, cancel this Agreement upon thirty (30) days’ prior written notice
to SCP unless SCP cures such breach and any intervening breach within such thirty (30) day period.



 


		16.2.2.	If Innocoll is in breach of its obligations under this Agreement then SCP may at its option cancel
this Agreement upon thirty (30) days prior written notice to Innocoll unless Innocoll cures such breach and any intervening breach
within such thirty (30) day period.



 


		16.2.3.	If the other party files a petition in bankruptcy, or applies for a consent to the appointment
of a receiver or trustee or suffers or permits the entry of an order adjudicating it to be bankrupt or insolvent.



 


		16.3.	Upon termination of this Agreement, only accounts payable and/or receivable and liabilities provided
for under this Agreement shall remain in effect, and neither party shall be entitled to any costs compensation or damages whatsoever
sustained resulting from, or arising out of or alleged to have been sustained, to have resulted from, or to have arisen out of
such termination.



 


		16.4.	Upon cancellation or expiration of this Agreement, SCP shall return all data, prospectuses and
materials including, without limitation, all copies of test results and other data accumulated, advertising and promotional materials
samples and instruments relating to the Products and in such event the distribution rights and all other rights granted to SCP
under this Agreement shall rev art to Innocoll and SCP shall not make further use of such technical information or disclose same.



 


		16.5.	Upon cancellation or expiration of this agreement, SCP shall immediately initiate the transfer
of the Product registration to Innocoll or its designee.



 


		16.6.	The termination of this Agreement shall not release either party from the obligation to make the
payment of any sum then owing, and it shall not release SCP from its obligation to pay Innocoll for all the Products ordered and
received, and Innocoll to deliver all the Products ordered which have been previously accepted by Innocoll as per section 3.2.



 


	17.		Miscellaneous Provisions



 


		17.1.	In case of force majeure, official orders, strike or lockout or similar hindrances which the parties
are unable to avert, the parties shall be released for the duration of such hindrance from the contractual obligations which they
are prevented from performing; provided however that if such suspension shall continue in excess of one hundred eighty (180)
days the parties shall meet and attempt to arrive at a mutually acceptable compromise within the spirit and intent of this Agreement.
In the event of shortage of production or supply of the Products for any reason Innocoll reserves the right to allocate



 




    	- 7 -



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

  


its supplies of the
Products to itself and such other distributors or customers as it deems equitable.


 


		17.2.	This Agreement shall be governed by and construed in accordance with the substantive provisions
of Irish law. Place of jurisdiction and forum for any disputes shall be Dublin, Ireland.



 


		17.3.	If individual provisions or rules of this Agreement are invalid or become invalid, the parties
hereby agree that this shall not affect the validity of the remainder of the terms and provisions. The parties undertake to replace
the invalid provisions by others which come closest to the effect originally intended.



 


		17.4.	This Agreement and its appendices which form an integral part of this Agreement and are incorporated
herein by reference, represents the entire agreement of the parties relating to the subject matter. The General Terms and Conditions
of each party shall not apply to this Agreement.



 


		17.5.	Any amendments to this Agreement or, the appendices may only be made by mutual agreement of the
parties, and must be in writing and executed by both parties.



 


		17.6.	Any expiration or termination of this Agreement shall not release the parties from liabilities
or obligations accrued as of the date thereof.



 


		17.7.	This Agreement shall not be assigned by Innocoll or SCP to any third party without the prior written
consent of the other Party.



 


		17.8.	This Agreement has been prepared in the English language, and English shall control its interpretation
and meaning.



 


IN WITNESS WHEREOF, the
parties have executed this Agreement as of the Effective Date.


 


	Saudi Centre for Pharmaceuticals	 	Innocoll
	Pharmaceuticals Limited	 	 
	 	 	 
	/s/ Dr. Khalid Alkhanbashi	 	/s/ Denise Carter
	Dr. Khalid Alkhanbashi	 	Denise Carter
	Deputy General Manager	 	Vice President Business Development


 


5/12/2011


 






    	- 8 -



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 










	Exhibit A:  Products


 


CollaGUARD Adhesion Barrier


 






    	Exhibit A-1



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 










	Exhibit B:  Prices & Conditions


 


***


 






    	Exhibit B-1



    	Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ]



    

 










	Exhibit C:  Minimum Annual Purchase Requirements


 


***


 




    	Exhibit C-1